Just Other Articles

Too often these days borrowers find themselves the victims of a money management system that simply does not work. The current magic bullet to get the average consumer is a mortgage loan

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

that pays off one debt while allowing the overspending and debt building use of the credit cord. Face it. We are a borrowing nation and we are in trouble. The current plague is known

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

as the interest only mortgage.

Loan companies continue to extend credit that reaches well beyond acceptable debt-to-income ratios – a dangerous practice to be sure. The average consumer

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

owing more than ever as they find themselves slowly being buried beneath ever-increasing credit card debt. It starts early on. Recruiters lining the halls of campus buildings, handing

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

out applications for major credit cards, promising credit to young, naive college students. Other consumers, not in college, but still a part of the overly zealous spending public, also

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

continue to flash their plastic as they buy their way further into debt. What is their ultimate plan for managing credit card debt? They will use an interest only mortgage to pay off th

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

e credit card debt that they continue to accrue but can’t really afford, ending up with credit card debt that isn’t really going down and a mortgage loan that continues to go up. As I sa

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

id, a money management system that is doomed.

The upside to the interest only mortgage is the way that it takes a non-deductible burgeoning debt and turns it into a tax deductible burgeo

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ning debt. Cool, huh? Not really. If you are spending more than you can afford, the interest only mortgage makes no sense to anyone but the mortgage company. They really don’t want yo

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

u to cut back your spending and manage your assets wisely. After all, such a competent financial decision on your part would mean less income on their part.

Instead of taking the lemmin

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

g approach of using mortgage companies that advertise their services of providing interest only mortgages in order to allow consumers with bad credit records to pay off their outstanding

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

credit card debt, consumers should instead be encouraged to consider how they spend their income. Learning to not overspend would solve the problems both now and in the future, where the

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

interest only mortgage offers no long term solutions on any level to any consumer. It’s simply a bad deal.

Sure, it is risky to finance consumers with bad credit. But a mortgage indic

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ates that there is a piece of good, solid collateral here. Risking a solid viable asset for an interest only loan is the classic text-book example of poor judgment. Incurring a mortgage

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

debt at any time is something that should be carefully considered and if the consumer doesn’t have a clear understanding of the concepts surrounding mortgages and interests, they can dec

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

isions that will affect them negatively for years to come – especially in the financial realm. Unfortunately, most of those affected by decisions like interest only mortgages are already

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

in the bad risk/bad credit/bad decision making history and so they feel cornered, without anywhere to turn.

It is completely mind boggling that with all the layers of regulations and st

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

atistics that are flashed to the public and published concerning good and bad credit ratings that the notion of an interest only loan is even legal. Where are the leaders who are suppose

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

d to predict and protect the lending industry? Certainly not paying attention to this concept, that is for sure! Maybe Alan Greenspan dozed off during the introduction of this particula

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

r mortgage loan option, but one thing is for sure – someone should wake him before the mortgage brokers find another brilliant idea to bring consumer debt to an even higher all-time high!

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justotherarticles.org.ua/article/89661/justotherarticles-No-Alternative-To-Managing-Credit-Card-Debt.html">No Alternative To Managing Credit Card Debt</a>

BB link (for phorums):
[url=http://www.justotherarticles.org.ua/article/89661/justotherarticles-No-Alternative-To-Managing-Credit-Card-Debt.html]No Alternative To Managing Credit Card Debt[/url]

Effective management during change is not as difficult as it many seem. Learn the practical steps & leadership attributes necessary to insure a healthy & productive environment even in the midst of upheaval.

Tags

Links

Just Other Articles - No Alternative To Managing Credit Card Debt

Related Articles: